Krystal Biotech (NASDAQ:KRYS) Stock Rating Raised to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Krystal Biotech (NASDAQ:KRYS) to a strong-buy rating in a research report report published on Thursday,Zacks reports.

A number of other brokerages also recently issued reports on KRYS. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective for the company. Citigroup raised their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Bank of America increased their target price on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. Finally, HC Wainwright lifted their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $377.20.

Krystal Biotech Trading Up 0.9%

KRYS opened at $344.96 on Thursday. The company has a fifty day moving average price of $343.58 and a two-hundred day moving average price of $314.97. Krystal Biotech has a 1-year low of $158.08 and a 1-year high of $382.54. The company has a market cap of $10.21 billion, a P/E ratio of 43.23 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. On average, research analysts forecast that Krystal Biotech will post 7.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently bought and sold shares of KRYS. Silvant Capital Management LLC purchased a new position in shares of Krystal Biotech during the second quarter worth approximately $30,000. Integrated Wealth Concepts LLC purchased a new position in Krystal Biotech in the 2nd quarter worth $46,000. Western Wealth Management LLC purchased a new stake in Krystal Biotech during the first quarter valued at about $34,000. USA Financial Formulas bought a new position in shares of Krystal Biotech during the first quarter valued at about $44,000. Finally, Versant Capital Management Inc increased its holdings in shares of Krystal Biotech by 189.2% in the second quarter. Versant Capital Management Inc now owns 214 shares of the company’s stock worth $80,000 after buying an additional 140 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.